Iovance Biotherapeutics, Inc. (IOVA)
8.60
+0.46
(+5.65%)
USD |
NASDAQ |
Sep 11, 16:00
8.615
+0.02
(+0.17%)
After-Hours: 20:00
Iovance Biotherapeutics Enterprise Value : 3.644B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 3.644B |
| September 10, 2026 | 3.436B |
| September 09, 2026 | 3.567B |
| September 08, 2026 | 3.689B |
| September 04, 2026 | 3.730B |
| September 03, 2026 | 3.689B |
| September 02, 2026 | 3.653B |
| September 01, 2026 | 3.499B |
| August 31, 2026 | 3.449B |
| August 28, 2026 | 3.377B |
| August 27, 2026 | 3.490B |
| August 26, 2026 | 3.408B |
| August 25, 2026 | 3.571B |
| August 24, 2026 | 3.399B |
| August 21, 2026 | 3.503B |
| August 20, 2026 | 3.821B |
| August 19, 2026 | 3.368B |
| August 18, 2026 | 2.933B |
| August 17, 2026 | 2.964B |
| August 14, 2026 | 2.910B |
| August 13, 2026 | 2.702B |
| August 12, 2026 | 2.801B |
| August 11, 2026 | 2.688B |
| August 10, 2026 | 2.647B |
| August 07, 2026 | 2.620B |
| Date | Value |
|---|---|
| August 06, 2026 | 2.561B |
| August 05, 2026 | 1.714B |
| August 04, 2026 | 1.723B |
| August 03, 2026 | 1.703B |
| July 31, 2026 | 1.592B |
| July 30, 2026 | 1.873B |
| July 29, 2026 | 1.814B |
| July 28, 2026 | 1.877B |
| July 27, 2026 | 1.968B |
| July 24, 2026 | 2.009B |
| July 23, 2026 | 2.072B |
| July 22, 2026 | 2.090B |
| July 21, 2026 | 2.231B |
| July 20, 2026 | 2.022B |
| July 17, 2026 | 2.013B |
| July 16, 2026 | 1.859B |
| July 15, 2026 | 1.895B |
| July 14, 2026 | 1.529B |
| July 13, 2026 | 1.578B |
| July 10, 2026 | 1.664B |
| July 09, 2026 | 1.728B |
| July 08, 2026 | 1.687B |
| July 07, 2026 | 1.719B |
| July 06, 2026 | 1.646B |
| July 02, 2026 | 1.701B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 247.31B |
| AVITA Medical, Inc. | 342.90M |
| Halozyme Therapeutics, Inc. | 14.14B |
| Neurocrine Biosciences, Inc. | 15.88B |
| Editas Medicine, Inc. | 274.14M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.32M |
| Revenue (Quarterly) | 99.31M |
| Total Expenses (Quarterly) | 146.63M |
| EPS Diluted (Quarterly) | -0.1051 |
| Gross Profit Margin (Quarterly) | 46.54% |
| Profit Margin (Quarterly) | -47.64% |
| Earnings Yield | -8.39% |
| Normalized Earnings Yield | -8.272 |